Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial
Name:
37030280.pdf
Size:
623.1Kb
Format:
PDF
Description:
Identified with Open Access button
Authors
Pignata, S.Oza, A.
Hall, G.
Pardo, B.
Madry, R.
Cibula, D.
Klat, J.
Montes, A.
Glasspool, R.
Colombo, N.
Pete, I.
Herrero Ibáñez, A.
Marín, M. R.
Ilieva, R.
Timcheva, C.
Di Maio, M.
Blakeley, C.
Taylor, R.
Barnicle, A.
Clamp, Andrew R
Affiliation
Istituto Nazionale Tumori 'Fondazione G Pascale', IRCCS, Napoli, Italy.Issue Date
2023
Metadata
Show full item recordAbstract
Background: The open-label, single-arm, multicenter ORZORA trial (NCT02476968) evaluated the efficacy and safety of maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer (PSR OC) who had tumor BRCA mutations (BRCAm) of germline (g) or somatic (s) origin or non-BRCA homologous recombination repair mutations (HRRm) and were in response to their most recent platinum-based chemotherapy after ≥2 lines of treatment. Methods: Patients received maintenance olaparib capsules (400 mg twice daily) until disease progression. Prospective central testing at screening determined tumor BRCAm status and subsequent testing determined gBRCAm or sBRCAm status. Patients with predefined non-BRCA HRRm were assigned to an exploratory cohort. The co-primary endpoints were investigator-assessed progression-free survival (PFS; modified Response Evaluation Criteria in Solid Tumors v1.1) in BRCAm and sBRCAm cohorts. Secondary endpoints included health-related quality of life (HRQoL) and tolerability. Results: 177 patients received olaparib. At the primary data cut-off (17 April 2020), the median follow-up for PFS in the BRCAm cohort was 22.3 months. The median PFS (95% CI) in BRCAm, sBRCAm, gBRCAm and non-BRCA HRRm cohorts was 18.0 (14.3-22.1), 16.6 (12.4-22.2), 19.3 (14.3-27.6) and 16.4 (10.9-19.3) months, respectively. Most patients with BRCAm reported improvements (21.8%) or no change (68.7%) in HRQoL and the safety profile was as expected. Conclusions: Maintenance olaparib had similar clinical activity in PSR OC patients with sBRCAm and those with any BRCAm. Activity was also observed in patients with a non-BRCA HRRm. ORZORA further supports use of maintenance olaparib in all patients with BRCA-mutated, including sBRCA-mutated, PSR OC.Citation
Pignata S, Oza A, Hall G, Pardo B, Madry R, Cibula D, et al. Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial. Gynecol Oncol. 2023 Apr 6;172:121-9. PubMed PMID: 37030280. Epub 2023/04/09. eng.Journal
Gynecologic OncologyDOI
10.1016/j.ygyno.2023.03.019PubMed ID
37030280Additional Links
https://dx.doi.org/10.1016/j.ygyno.2023.03.019Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ygyno.2023.03.019
Scopus Count
Collections
Related articles
- Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
- Authors: Cadoo K, Simpkins F, Mathews C, Liu YL, Provencher D, McCormick C, ElNaggar AC, Altman AD, Gilbert L, Black D, Kabil N, Bennett J, Munley J, Aghajanian C
- Issue date: 2022 Sep
- Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
- Authors: Poveda A, Lheureux S, Colombo N, Cibula D, Lindemann K, Weberpals J, Bjurberg M, Oaknin A, Sikorska M, González-Martín A, Madry R, Pérez MJR, Ledermann J, Davidson R, Blakeley C, Bennett J, Barnicle A, Škof E
- Issue date: 2022 Mar
- Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
- Authors: Tappenden P, Harnan S, Ren S, Thokala P, Wong R, Mukuria C, Green C, Pledge S, Tidy J
- Issue date: 2017 Jan
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
- Authors: Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U
- Issue date: 2014 Jul
- Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
- Authors: Pujade-Lauraine E, Selle F, Scambia G, Asselain B, Marmé F, Lindemann K, Colombo N, Mądry R, Glasspool R, Vergote I, Korach J, Lheureux S, Dubot C, Oaknin A, Zamagni C, Heitz F, Gladieff L, Rubio-Pérez MJ, Scollo P, Blakeley C, Shaw B, Ray-Coquard I, Redondo A, OReO/ENGOT-ov38 investigators
- Issue date: 2023 Dec